1247 related articles for article (PubMed ID: 25999708)
1. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.
Raluy-Callado M; Lambrelli D; MacLachlan S; Khalid JM
Int J Chron Obstruct Pulmon Dis; 2015; 10():925-37. PubMed ID: 25999708
[TBL] [Abstract][Full Text] [Related]
2. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of prevalent and new COPD cases in Greece: the GOLDEN study.
Mitsiki E; Bania E; Varounis C; Gourgoulianis KI; Alexopoulos EC
Int J Chron Obstruct Pulmon Dis; 2015; 10():1371-82. PubMed ID: 26229456
[TBL] [Abstract][Full Text] [Related]
4. Impact of using the new GOLD classification on the distribution of COPD severity in clinical practice.
Hernández M; García G; Falco J; García AR; Martín V; Ibarrola M; Quadrelli S
Int J Chron Obstruct Pulmon Dis; 2018; 13():351-356. PubMed ID: 29403272
[TBL] [Abstract][Full Text] [Related]
5. The distribution of COPD in UK general practice using the new GOLD classification.
Haughney J; Gruffydd-Jones K; Roberts J; Lee AJ; Hardwell A; McGarvey L
Eur Respir J; 2014 Apr; 43(4):993-1002. PubMed ID: 24176990
[TBL] [Abstract][Full Text] [Related]
6. 2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group.
Högman M; Sulku J; Ställberg B; Janson C; Bröms K; Hedenström H; Lisspers K; Malinovschi A
Int J Chron Obstruct Pulmon Dis; 2018; 13():165-173. PubMed ID: 29379281
[TBL] [Abstract][Full Text] [Related]
7. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
Rebordosa C; Plana E; Aguado J; Thomas S; García-Gil E; Perez-Gutthann S; Castellsague J
Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):126-133. PubMed ID: 29740896
[TBL] [Abstract][Full Text] [Related]
8. Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study.
Cabrera C; Casanova C; Martín Y; Mirabal V; Sánchez Mdel C; Álvarez F; Juliá G; Cabrera-Navarro P; García-Bello MÁ; Marín JM; de-Torres JP; Divo M; Celli B
Int J Chron Obstruct Pulmon Dis; 2016; 11():1217-22. PubMed ID: 27354780
[TBL] [Abstract][Full Text] [Related]
9. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity.
Mapel DW; Dalal AA; Johnson PT; Becker LK; Hunter AG
Int J Chron Obstruct Pulmon Dis; 2015; 10():1477-86. PubMed ID: 26251587
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis.
Lopez-Campos JL; Fernandez-Villar A; Calero-Acuña C; Represas-Represas C; Lopez-Ramírez C; Fernández VL; Soler-Cataluña JJ; Casamor R;
Int J Chron Obstruct Pulmon Dis; 2015; 10():975-84. PubMed ID: 26064045
[TBL] [Abstract][Full Text] [Related]
11. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations.
Jones PW; Nadeau G; Small M; Adamek L
Respir Med; 2014 Jan; 108(1):129-35. PubMed ID: 24041746
[TBL] [Abstract][Full Text] [Related]
13. COPD exacerbations by disease severity in England.
Merinopoulou E; Raluy-Callado M; Ramagopalan S; MacLachlan S; Khalid JM
Int J Chron Obstruct Pulmon Dis; 2016; 11():697-709. PubMed ID: 27099486
[TBL] [Abstract][Full Text] [Related]
14. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study.
Gunen H; Yilmaz M; Aktas O; Ergun P; Ortakoylu MG; Demir A; Cetinkaya P; Gurgun A; Otlu M; Cilli A; Yilmaz U; Kokturk N; Candemir I; Yakar HI; Ar I; Konya A
Int J Chron Obstruct Pulmon Dis; 2015; 10():2485-94. PubMed ID: 26622176
[TBL] [Abstract][Full Text] [Related]
15. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.
Chalmers JD; Tebboth A; Gayle A; Ternouth A; Ramscar N
NPJ Prim Care Respir Med; 2017 Jun; 27(1):43. PubMed ID: 28663549
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis.
Fernández-Villar A; López-Campos JL; Represas Represas C; Marín Barrera L; Leiro Fernández V; López Ramírez C; Casamor R
Int J Chron Obstruct Pulmon Dis; 2015; 10():961-7. PubMed ID: 26028969
[TBL] [Abstract][Full Text] [Related]
17. The PLATINO study: description of the distribution, stability, and mortality according to the Global Initiative for Chronic Obstructive Lung Disease classification from 2007 to 2017.
Menezes AM; Wehrmeister FC; Perez-Padilla R; Viana KP; Soares C; Müllerova H; Valdivia G; Jardim JR; Montes de Oca M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1491-1501. PubMed ID: 28553101
[TBL] [Abstract][Full Text] [Related]
18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
19. What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.
Gayle A; Dickinson S; Morris K; Poole C; Mathioudakis AG; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2018; 13():3485-3492. PubMed ID: 30498338
[TBL] [Abstract][Full Text] [Related]
20. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
Ivanov Y; Nikolaev I; Nemeth I
Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
